A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

December 28, 2020

Study Completion Date

May 25, 2021

Conditions
Hypoparathyroidism
Interventions
DRUG

PCO371

PCO371 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (11)

1083

Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika, Budapest

19107

Thomas Jefferson University, Philadelphia

40536

University of Kentucky, Lexington

43210

Ohio State University Wexner Medical Center, Columbus

46202

Indiana University School of Medicine, Indianapolis

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

90502

The Lundquist Institute, Torrance

02114

Massachusetts General Hospital, Boston

G1V 4G2

Endocrinologie et néphrologie Centre de recherche du CHU de Québec, Québec

L6M 1M1

McMaster University Bone Research & Education Centre, Oakville

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY